163 related articles for article (PubMed ID: 19949026)
1. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Karacay H; Sharkey RM; Gold DV; Ragland DR; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
J Nucl Med; 2009 Dec; 50(12):2008-16. PubMed ID: 19949026
[TBL] [Abstract][Full Text] [Related]
2. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Gold DV; Schutsky K; Modrak D; Cardillo TM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
[TBL] [Abstract][Full Text] [Related]
3. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
4. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Gold DV; Modrak DE; Schutsky K; Cardillo TM
Int J Cancer; 2004 Apr; 109(4):618-26. PubMed ID: 14991585
[TBL] [Abstract][Full Text] [Related]
5. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
6. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Ocean AJ; Pennington KL; Guarino MJ; Sheikh A; Bekaii-Saab T; Serafini AN; Lee D; Sung MW; Gulec SA; Goldsmith SJ; Manzone T; Holt M; O'Neil BH; Hall N; Montero AJ; Kauh J; Gold DV; Horne H; Wegener WA; Goldenberg DM
Cancer; 2012 Nov; 118(22):5497-506. PubMed ID: 22569804
[TBL] [Abstract][Full Text] [Related]
7. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.
Sharkey RM; Karacay H; Govindan SV; Goldenberg DM
Mol Cancer Ther; 2011 Jun; 10(6):1072-81. PubMed ID: 21467164
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
9. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Picozzi VJ; Ramanathan RK; Lowery MA; Ocean AJ; Mitchel EP; O'Neil BH; Guarino MJ; Conkling PR; Cohen SJ; Bahary N; Frank RC; Dragovich T; Bridges BB; Braiteh FS; Starodub AN; Lee FC; Gribbin TE; Richards DA; Lee M; Korn RL; Pandit-Taskar N; Goldsmith SJ; Intenzo CM; Sheikh A; Manzone TC; Horne H; Sharkey RM; Wegener WA; O'Reilly EM; Goldenberg DM; Von Hoff DD
Eur J Cancer; 2015 Sep; 51(14):1857-64. PubMed ID: 26187510
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
11. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
Al-Ejeh F; Darby JM; Brown MP
PLoS One; 2009; 4(2):e4630. PubMed ID: 19247485
[TBL] [Abstract][Full Text] [Related]
13. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
Cardillo TM; Blumenthal R; Ying Z; Gold DV
Int J Cancer; 2002 Jan; 97(3):386-92. PubMed ID: 11774294
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.
Cardillo TM; Ying Z; Gold DV
Clin Cancer Res; 2001 Oct; 7(10):3186-92. PubMed ID: 11595713
[TBL] [Abstract][Full Text] [Related]
15. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
Stein R; Chen S; Reed L; Richel H; Goldenberg DM
Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
[TBL] [Abstract][Full Text] [Related]
16. Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Sugyo A; Tsuji AB; Sudo H; Koizumi M; Ukai Y; Kurosawa G; Kurosawa Y; Saga T; Higashi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274301
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
18. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
